Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 6/20 | 1.00 |
| ▸ | GRIN2A | Q12879 | 6/20 | 1.00 |
| ▸ | GRIN2D | O15399 | 5/20 | 1.00 |
| ▸ | GRIN3B | O60391 | 5/20 | 1.00 |
| ▸ | GRIN2B | Q13224 | 5/20 | 1.00 |
| ▸ | GRIN2C | Q14957 | 5/20 | 1.00 |
| ▸ | GRIN3A | Q8TCU5 | 5/20 | 1.00 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | MTOR | P42345 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11656535 | 0.98 | GRIN1 (0.95) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Hydrochloric Acid SCHEMBL31202654 | 0.98 | GRIN1 (0.95) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| SCHEMBL5608355 | 0.84 | GRIN2D (0.71) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| SCHEMBL1072142 | 0.83 | GRIN1 (0.71) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| SCHEMBL8061377 | 0.83 | GRIN1 (0.71) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| SCHEMBL8295099 | 0.82 | GRIN1 (0.70) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| SCHEMBL5270620 | 0.79 | GRIN1 (0.65) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| SCHEMBL2480001 | 0.79 | GRIN1 (0.65) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| SCHEMBL13287394 | 0.79 | GRIN2D (0.65) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| SCHEMBL812216 | 0.79 | GRIN1 (0.68) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9453017-B2 | Antiviral therapies with phospholipase D inhibitors | VANDERBILT UNIVERSITY (US) | 2016-09-27 | — | — | US | claimed |
| US-20120157537-A1 | NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau | IQBAL KHALID (US) | 2012-06-21 | — | — | US | claimed |
| US-20090124659-A1 | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase and inhibitors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-05-14 | — | — | US | claimed |
| US-20090005459-A1 | NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau | IQBAL KHALID | 2009-01-01 | — | — | US | claimed |
| EP-1682109-B1 | THE USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENIC AS PEPTIDES IN AMYLOIDOPATHIES | MERZ PHARMA GMBH & CO KGAA (DE) | 2008-10-15 | — | — | EP | claimed |
| EP-1838297-A1 | 1-AMINOCYCLOHEXANE-DERIVATIVES FOR THE TREATMENT OF MULTIPLE SCLEROSIS EMOTIONAL LABILITY AND PSEUDOBULBAR AFFECT | Merz Pharma GmbH & Co. KGaA (DE) | 2007-10-03 | — | — | EP | claimed |
| CN-1282452-C | Use of aminoadamantane compounds as immunomodulators | MERZ & CO GMBH & CO (DE) | 2006-11-01 | — | — | CN | claimed |
| US-20060205822-A1 | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect | FOREST LABORATORIES, INC. (US) | 2006-09-14 | — | — | US | claimed |
| WO-2006069294-A1 | 1-AMINOCYCLOHEXANE-DERIVATIVES FOR THE TREATMENT OF MULTIPLE SCLEROSIS EMOTIONAL LABILITY AND PSEUDOBULBAR AFFECT | MERZ PHARMA GMBH & CO. KGAA (DE) | 2006-06-29 | — | — | WO | claimed |
| EP-1556019-A2 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | Merz Pharma GmbH & Co. KGaA (DE) | 2005-07-27 | — | — | EP | claimed |
| WO-2004037234-A2 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2004-05-06 | — | — | WO | claimed |
| WO-2004009062-A2 | NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF MICROTUBULE ASSOCIATED PROTEIN tau | IQBAL KHALID (US) | 2004-01-29 | — | — | WO | claimed |
| US-20040019118-A1 | NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau | IQBAL KHALID (US) | 2004-01-29 | — | — | US | claimed |
| EP-1293201-A2 | Use of aminoadamantane compounds as immunoregulators | Merz Pharma GmbH & Co.KGaA (DE) | 2003-03-19 | — | — | EP | claimed |
| EP-0845984-B1 | USE OF AMINOADAMANTANE COMPOUNDS AS IMMUNOREGULATORS | MERZ PHARMA GMBH & CO KGAA (DE) | 2003-03-12 | — | — | EP | claimed |
| US-6255348-B1 | AIDS THERAPY | MERZ + CO. GMBH & CO. (DE) | 2001-07-03 | — | — | US | claimed |
| US-6172116-B1 | NEUTROPHIL ACTIVATION; TREATING AUTOIMMUNE DISEASES | MERZ + CO. GMBH & CO. (DE) | 2001-01-09 | — | — | US | claimed |
| CN-1198669-A | Use of aminoadamantane compounds as immunomodulators | MERZ & CO GMBH & CO (DE) | 1998-11-11 | — | — | CN | claimed |
| EP-0845984-A1 | USE OF AMINOADAMANTANE COMPOUNDS AS IMMUNOREGULATORS | MERZ + CO. GmbH & Co. (DE) | 1998-06-10 | — | — | EP | claimed |
| WO-1997007791-A1 | USE OF AMINOADAMANTANE COMPOUNDS AS IMMUNOREGULATORS | MERZ + CO. GMBH & CO. (DE) | 1997-03-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157537-A1 | NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau | GRIN1, GRIN2A, MAPT | GRIN1 1/4885GRIN2A 2/4885GRIN2D 12/4885 |
| US-20090005459-A1 | NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau | GRIN1, GRIN2A, MAPT | GRIN1 1/4885GRIN2A 2/4885GRIN2D 12/4885 |
| US-20040019118-A1 | NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau | GRIN2A, GRIN1, MAPT | GRIN1 2/4885GRIN2A 1/4885GRIN2D 14/4885 |
| US-20090124659-A1 | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase and inhibitors | ACHE, BACE1, BCHE | GRIN1 26/4885GRIN2A 36/4885GRIN2D 140/4885 |
| US-20060205822-A1 | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect | NMBR, NMUR1, CNR1 | GRIN1 207/4885GRIN2A 134/4885GRIN2D 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.